Open AccessPembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma
Author(s) -
Justine Lavaud,
Astrid Blom,
Christine Longvert,
M. Le Fort,
Elisa FunckBrentano,
Philippe Saïag
Publication year - 2019
Publication title -
european journal of dermatology/ejd. european journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.48
H-Index - 71
eISSN - 1952-4013
pISSN - 1167-1122
DOI - 10.1684/ejd.2019.3671
Subject(s) - pembrolizumab , medicine , radiation therapy , discontinuation , oncology , concomitant , merkel cell carcinoma , cancer , carcinoma , immunotherapy
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent non-melanoma skin cancer. Treatment options for inoperable advanced cSCC cases are limited. The efficacy of anti-programmed cell death-1 (PD-1) monoclonal antibodies (mAb) has been reported recently in some patients with cSCC.